IP Library Granted Patent US 8,236,340
Granted Patent B2
US 8,236,340 · App. 12/136,576 · Granted Aug 7, 2012

Drug formulations for coating medical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,236,340
App. No.
12/136,576
Granted
Aug 7, 2012
Kind
B2
Abstract

The present invention relates to oil-based formulations of hydrophobic drugs for the uniform coating of medical devices such as vascular stents and balloons. Another aspect of the present invention is an intravascular medical device having an oil-based coating suitable for delivering a water-insoluble drug, comprising one or more of an anti-oxidant, an anti-inflammatory and an anti-restenotic agent.

Claims (19)

1. A medical device comprising a coating,

wherein the coating comprises i) a non-volatile oil-based solvent, ii) a hydrophobic therapeutic agent selected from the group consisting of rapamycin, rapamycin analogs, ABT-578, everolimus, paclitaxel, dexamethasone, ceramides, dimethyl sphingosine, ether-linked diglycerides, ether-linked phosphatidic acids, sphinganines, steroids, taxol, taxol analogs, actinomycin D, prostaglandins, vitamin A, probucol, Batimastat, Statins, Trapidil, and Cytochalasin B, and iii) an amount of volatile solvent sufficient to decrease the viscosity of the non-volatile oil-based solvent,

wherein the hydrophobic therapeutic agent is transferrable to a vessel upon contact therewith and is uniformly dispersed over the medical device within the non-volatile oil-based solvent.

2. The medical device of claim 1 , wherein the medical device is an intravascular balloon.

3. The medical device of claim 1 , wherein the medical device is an intravascular stent.

4. The medical device of claim 1 , wherein the oil-based solvent comprises Vitamin E.

5. The medical device of claim 1 , wherein the hydrophobic therapeutic agent is a restenosis-inhibiting agent.

6. The medical device of claim 5 , wherein the restenosis-inhibiting agent is selected from rapamycin, paclitaxel, or their analogs.

7. The drug-coated intravascular device produced by a method comprising:

producing a coating composition by mixing a drug composition comprising a drug and an oil-based non-volatile solvent in a volatile solvent,

coating said intravascular device with said coating composition; and

causing said volatile solvent to evaporate.

8. The medical device of claim 1 , wherein the medical device is an intravascular medical device.

9. The medical device of claim 1 , wherein the medical device is an expandable medical device.

10. The medical device of claim 1 , wherein the volatile solvent comprises ethanol or isopropanol.

11. The medical device of claim 1 , wherein the dissolution rate of the hydrophobic therapeutic agent is compatible with sustained release delivery of the hydrophobic therapeutic agent to an artery wall.

12. The medical device of claim 1 , wherein the coating comprises a base consisting of an oil capable of dispersing the hydrophobic therapeutic agent, so as to provide a lubricious surface to the medical device without using polymers or hydrogels.

13. The medical device of claim 12 , wherein the coating base is a non-polymer base.

14. The medical device of claim 12 , wherein the coating base is a non-hydrogel base.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2020
From: REVA MEDICAL, INC.
To: REVA MEDICAL, LLC
Reel/Frame 054778/0748 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Feb 27, 2020
From: GOLDMAN SACHS INTERNATIONAL, AS ADMINISTRATIVE AGENT
To: REVA MEDICAL, INC.
Reel/Frame 052045/0383 →
NOTICE OF GRANT OF SECURITY INTEREST IN U.S. PATENTS Recorded Apr 9, 2019
From: REVA MEDICAL, INC.
To: GOLDMAN SACHS INTERNATIONAL AS ADMINISTRATIVE AGENT
Reel/Frame 048834/0001 →